The direct cost of patients with multiple sclerosis: A survey from Italian MS centres

Neurological Sciences

Volumn 32, Issue 6, 2011, Pages 1035-1041

  Berto, P ^a   Amato, M P ^b   Bellantonio, P ^c   Bortolon, F ^d   Cavalla, P ^e   Florio, C ^f   Lugaresi, A ^g   Montanari, E ^h   Rottoli, M ⁱ   Simone, I L ^j   Zaffaroni, M ^k  

^a PBE Consulting srl   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c IRCCS NEUROMED   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f CARDARELLI HOSPITAL   (Italy)

^g UNIVERSITY OF CHIETI   (Italy)

^h Ospedale Civile   (Italy)

ⁱ OSPEDALI RIUNITI   (Italy)

^j UNIVERSITY OF BARI   (Italy)

^k Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

more..

Author keywords

Cost; Disease modifying biologics; Italy; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; NATALIZUMAB;

CONTROLLED STUDY; COST OF ILLNESS; DIAGNOSTIC TEST; DISEASE COURSE; DRUG COST; HEALTH CARE; HEALTH CARE COST; HOSPITAL COST; HUMAN; ITALY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; RESOURCE MANAGEMENT; REVIEW;

EID: 84942303215     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-011-0578-4     Document Type: Review

References (25)

1. Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182-191 (Pubitemid 34792722)
2. Amato MP, Battaglia MA, Caputo D, Fattore G, Gerzeli S, Pitaro M et al (2002) The costs of multiple sclerosis: A cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 249(2): 152-163 (Pubitemid 34143469)
3. Kobelt G, Pugliatti M (2005) Cost of multiple sclerosis in Europe. Eur J Neurol 12(Suppl 1):63-67 (Pubitemid 40755607)
4. Kobelt G (2004) Economic evidence in multiple sclerosis: A review. EurJ Health Econ 5(Suppl 1):S54-S62 (Pubitemid 39440398)
5. Kobelt G (2006) Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 7(Suppl 2):S24-S33
6. Kobelt G, Berg J, Lindgren P, Jonsson B (2006) Costs and quality of life in multiple sclerosis in Europe: Method of assessment and analysis. Eur J Health Econ 7(Suppl 2):S5-S13
7. Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A (2006) Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 7(Suppl 2):S45-S54
8. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B (2006) Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 77(8):918-926 (Pubitemid 44174075)
9. Kobelt G, Texier-Richard B, Lindgren P (2009) The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. Mult Scler 15(6):741-751
10. Vosoughi R, Freedman MS (2010) Therapy of MS. Clin Neurol Neurosurg 112(5):365-385
11. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, et al. (2004) Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects. Neurology 62(11):2038-2043 (Pubitemid 38738218)
12. Kobelt G, Berg J, Atherly D, Hadjimichael O (2006) Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States. Neurology 66(11):1696-1702 (Pubitemid 43964625)
13. Ministero della Salute. Aggiornamento delle tariffe delle prestazioni di assistenza ospedaliera. Decreto Ministeriale 13/12/2006. www.sanita.it
14. Ministero della Salute. Tempi Medi di Attivitá, Modalitá di Esecuzione (2006). Nomenclatore delle Prestazioni Specialistiche Ambulatoriali Territoriali. www.sanita.it
15. GIOFIL (2009). Prontuario Farmaci del Sistema Sanitario Nazionale. www.giofil.it
16. Asche CV, Ho E, Chan B, Coyte PC (1997) Economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand 95(5):268-274 (Pubitemid 27214475)
17. Bourdette DN, Prochazka AV, Mitchell W, Licari P, Burks J (1993) Health care costs of veterans with multiple sclerosis: Implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group. Arch Phys Med Rehabil 74(1):26-31 (Pubitemid 23033294)
18. Grudzinski AN, Hakim Z, Cox ER, Bootman JL (1999) The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. Pharmacoeconomics 15(3):229-240 (Pubitemid 29133460)
19. Henriksson F, Jonsson B (1998) The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 13(5 Pt 2): 597-606
20. Murphy N, Confavreux C, Haas J, Konig N, Roullet E, Sailer M (1998) Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 13(5 Pt 2):607-622
21. Pope GC, Urato CJ, Kulas ED, Kronick R, Gilmer T (2002) Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 58(1):37-43 (Pubitemid 34041935)
22. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED (1998) A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 4(5):419-425 (Pubitemid 28515352)
23. Russo P, Capone A, Paolillo A, Macchia F, Ranzato F, Costantino G et al (2004) Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Investig 24(7):409-420 (Pubitemid 38951792)
24. Kobelt G, Kasteng F (2009) Access to innovative treatments in Multiple Sclerosis in Europe. A report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA)
25. Henriksson F, Fredrikson S, Masterman T, Jonsson B (2001) Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden. Eur J Neurol 8(1):27-35 (Pubitemid 32154571)